The aging mice were frail, their grip weakening and their bones thinning. Then researchers gave them back a single protein their muscles had stopped making, and the animals got stronger. They ran longer on treadmills, processed blood sugar more efficiently, and held onto bone that would otherwise have crumbled. The protein, called CLCF1, is one the body normally pumps out during exercise. But its levels drop as organisms age, and a team led by Kang and colleagues has now shown, in a study published in Nature Communications in June 2025, that restoring it can reverse several hallmarks of physical decline in old male mice.
The finding offers one of the clearest biological explanations yet for a frustrating reality of aging: exercise becomes less effective at protecting the body even when older adults keep doing it. CLCF1 belongs to a class of signaling molecules called myokines, proteins that muscles release into the bloodstream during physical effort. If the muscle stops sending the signal, downstream tissues never get the memo.
From human data to mouse experiments
The research did not start in a mouse cage. Kang’s team first turned to a publicly available human dataset in the Gene Expression Omnibus, which contains gene activity profiles from younger and older adults who completed resistance exercise sessions and a 12-week progressive training program. When the researchers reanalyzed that data, one pattern stood out: CLCF1 gene expression rose after training in younger participants but barely budged in older ones.
That age-dependent gap became the hypothesis. If older muscles fail to produce enough CLCF1 even when they exercise, could supplying the protein externally recover some of what aging takes away?
What happened when old mice got the protein back
In the animal experiments, aged male mice that received CLCF1 showed measurable gains across several systems. Grip strength improved. Treadmill endurance increased. Glucose tolerance, a marker of metabolic health that typically worsens with age, got better. Inside the muscle tissue, mitochondria, the structures that generate cellular energy, ramped up their output.
The surprises came from bone. Assessments showed that CLCF1-treated mice retained more bone density than untreated controls, with shifts in the balance between osteoclasts (cells that break bone down) and osteoblasts (cells that build it up) tilting toward preservation. The paper details blocking experiments and cell-level assays tracing how the protein influences bone remodeling pathways, suggesting CLCF1 acts on multiple tissues rather than muscle alone.
What makes this approach distinctive is that the researchers were not forcing old mice to exercise harder. They were replacing a specific molecular signal that age had blunted, essentially mimicking part of the chemical signature of a workout without requiring the workout itself. For older organisms whose capacity to train is already limited by pain, fatigue, or frailty, that distinction could eventually matter a great deal.
A second study targets the other side of the equation
A separate line of research strengthens the broader case that fine-tuning inflammatory signals can extend healthy aging. In a 2024 study published in Nature, Widjaja and colleagues reported that a pro-inflammatory molecule called IL-11 accumulates with age and that genetically deleting or blocking IL-11 with antibodies in older mice extended median lifespan while reducing fibrosis and improving physical function across multiple organs.
The two studies represent opposite strategies aimed at the same problem. CLCF1 restoration adds back a beneficial signal that fades. IL-11 inhibition removes a harmful signal that builds up. Both converge on the same outcome: less chronic, low-grade inflammation and better late-life resilience in mice. Together, they suggest that the inflammatory network driving age-related decline has specific, addressable nodes, not just a generalized fog of damage.
Where the science hits its limits
The strongest caveat is species distance. Every CLCF1 intervention result comes from aged male mice. The human evidence so far is limited to gene expression data, which measures how actively a gene is being read, not how much functional protein ends up circulating in the blood. Gene expression and protein levels do not always move in lockstep; post-transcriptional regulation, protein stability, and clearance rates all introduce gaps. No published study has measured circulating CLCF1 protein in human blood before and after exercise or aging, and no human dosing or safety data exist.
The male-only design is another limitation. Hormonal differences in aging muscle and bone metabolism could substantially alter how the protein works in female animals or, eventually, in women. Conditions like osteoporosis already show strong sex-based differences in prevalence and progression. Until female mice are included in CLCF1 studies, claims about broad applicability remain preliminary.
On the data-sharing front, the primary datasets for the mouse bone and muscle endpoints do not include linked public metabolomic or proteomic files. Independent researchers can verify the human transcriptomic reanalysis because that dataset is openly available, but replicating the molecular-level claims about mitochondria and osteoclast activity from raw shared data is not yet possible. That does not invalidate the findings, but it slows the kind of independent scrutiny that builds confidence.
Neither the CLCF1 nor the IL-11 research teams have published statements about translational timelines, human dosing strategies, or anticipated safety concerns. The IL-11 work is somewhat further along because antibody-based tools already exist that could, in principle, be adapted for clinical use. But even that program has not produced published human efficacy data for lifespan extension or frailty reduction. Both approaches remain preclinical.
Real-world complexity adds another layer of uncertainty. The mouse studies used standardized diets and controlled housing. Older humans typically live with diabetes, cardiovascular disease, chronic kidney impairment, or combinations of all three. Any of those conditions could change how an inflammatory pathway responds to manipulation, and drug interactions would need careful evaluation if CLCF1-based therapies or IL-11-blocking antibodies ever reach clinical testing.
What this means for people watching the aging research space
Two tiers of evidence underpin this story, and keeping them separate matters. The first tier is peer-reviewed mouse intervention data from high-impact journals, showing that changing specific inflammatory or exercise-linked signals can measurably improve strength, metabolism, bone health, and survival in aged animals. These are functional results in living organisms, not just cell-culture observations.
The second tier is the human gene expression data. It is real, it is publicly available, and it pointed researchers toward CLCF1 in the first place. But it does not prove that CLCF1 protein declines in aging human blood or that restoring it would reproduce the mouse results.
The most grounded reading, as of June 2025, is this: specific nodes in the inflammatory network can be tuned in ways that improve late-life health in animals. Whether similar levers exist in people, and whether pulling them would be safe, remains an open question. But the fact that two independent research groups, working on different molecules through different mechanisms, arrived at overlapping improvements in aged mice suggests the underlying biology is real and worth pursuing. For anyone who has watched an older relative lose strength despite staying active, the idea that a missing protein might be part of the explanation is, at minimum, a lead worth following.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
